Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
NCT07035405Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of colchicine in ischemic stroke, sponsored by Beijing Tiantan Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07035405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035405.